Aptose Biosciences Inc. (APTO)

Market Cap	19.46M
Revenue (ttm)	n/a
Net Income (ttm)	-49.25M
Shares Out	7.30M
EPS (ttm)	-7.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	2.43
Previous Close	2.40
Day's Range	2.38 - 2.50
52-Week Range	0.36 - 6.60
Beta	1.38
Analysts	Strong Buy
Price Target	37.67 (+1,440.82%)
Earnings Date	Nov 9, 2023

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: APTO

Analyst Forecast

According to 6 analysts, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is $37.67, which is an increase of 1,440.82% from the latest price.

Price Target

$37.67

(1,440.82% upside)

Analyst Consensus: Strong Buy